JNM Podcast

Episode 10 – Understanding Metabolic PET Markers Beyond SUV

Standardized uptake values (SUV) measure a patient's response to nuclear medicine therapy. But what other markers of success are there, and do these markers and the interpretation of them vary depending on the disease being imaged? Sally Barrington, MD, works specifically on lymphoma and shares her expertise on what markers of success and criteria are critical to her in understanding patients' responses to treatment.  Joining her, along with our host Ken Herrmann, MD, are Louise Emmett, MD, and Irène Buvat, PhD. The panel also discusses the role of AI tools in analyzing risk and response assessment in lymphoma. Tune in now!

Click the description found here to see additional resources provided by Dr. Barrington: 

Moderator: Ken Herrmann, MD (Universitätsmedizin Essen, Essen, Germany)

Panelists: Sally Barrington, MD (Kings College London, London, United Kingdom), Louise Emmett, MD (University of New South Wales, Sydney, Australia), and Irène Buvat, PhD (Institut Curie, Paris, France)

Thank you to SOFIE Biosciences for sponsoring this episode.

YouTube: Understanding Metabolic PET Markers Beyond SUV

Audio: Understanding Metabolic PET Markers Beyond SUV

Episode 9 – PSMA PET: From Adolescence to Adulthood
Is PSMA becoming so regularly used that it's...boring? Not according to this lively discussion. Join us for episode 9 of the JNM Podcast, where host Ken Herrmann discusses the state of PSMA PET with experts Thomas Hope, Oliver Sartor, and Wolfgang Fendler. The panel talks about PSMA PET in clinical trials vs. real-life disease management, appropriate use criteria and its evolution, and patient and treatment data. Plus, what's next for PSMA as it matures into adulthood? Tune in to find out!

Moderator: Ken Herrmann, MD (Universitätsmedizin Essen, Essen, Germany)

Panelists: Thomas Hope, MD (University of California, San Francisco, San Francisco, California, United States), Oliver Sartor, MD (Mayo Clinic, Rochester, Minnesota, United States), and Wolfgang Fendler, MD (Essen University Hospital, Essen, Germany)

Thank you to SOFIE Biosciences for sponsoring this episode.

YouTube: PSMA PET: From Adolescence to Adulthood

Audio: PSMA PET: From Adolescence to Adulthood

Episode 8 – Revolutionizing Cardiovascular Imaging with Flurpiridaz
The JNM Podcast is back in 2025! Join Ken Herrmann, MD, and co-moderator Frank Bengel, MD, for an episode on cardiovascular perfusion imaging. In the U.S., SPECT imaging makes up five to six million studies per year. But PET studies make up just 2.2 million, and only 7%, or 150,000 of those, are cardiac PET imaging. But that may be about to change. The FDA has recently approved Flurpiridaz F-18, which may make cardiac imaging more accessible to patients across the country. Here to discuss the utility of the F-18 label and the future of myocardial perfusion imaging are Jamshid Maddahi, MD, FACC, FASNC, and Sharmila Dorbala, MD, MPH.

Moderators: Ken Herrmann, MD (Universitätsmedizin Essen, Essen, Germany) and Frank Bengel, MD (Hanover Medical School, Hanover, Germany)

Panelists: Sharmila Dorbala, MD, MPH (Brigham and Women’s Hospital, Boston, Massachusetts, United States) and Jamshid Maddahi, MD, FACC, FASNC (UCLA School of Medicine, Los Angeles, California, United States)

Thank you to GE HealthCare for sponsoring this episode.

YouTube: Revolutionizing Cardiovascular Imaging with Flurpiridaz

Audio: Revolutionizing Cardiovascular Imaging with Flurpiridaz

Episode 7 – Social Media in (Nuclear) Medicine
Get ready for an episode that's a bit...meta. In Episode 7, our host Ken Herrmann is joined by the podcasters behind GU Cast: Declan Murphy, FRACS, FRCS, and Renu Eapen, MBBS, FRACS. Together with Wolfgang Weber, MD, PhD, they discuss how social media has shaped the landscape of medicine - from how we get medical news, to sharing new research to interacting with colleagues and patients. Tune in now!

Moderator: Ken Herrmann, MD (Universitätsmedizin Essen, Essen, Germany)

Panelists: Declan Murphy, FRACS, FRCS (Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia), Renu Eapen, MBBS, FRACS (Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia), and Wolfgang Weber, MD, PhD (Technical University of Munich, München, Germany)

Thank you to SOFIE Biosciences for sponsoring this episode.

YouTube: Social Media in (Nuclear) Medicine

Audio: Social Media in (Nuclear) Medicine

Episode 6 – Bringing PRRT to First Line: NETTER-2
Join us for episode 6 of the JNM podcast. Moderator Ken Herrmann, MD is joined by Simron Singh, MD and Lisa Bodei, MD, PhD to discuss NETTER-2. NETTER-2 was the first trial to examine radioligand therapy as a first-line therapy for cancers, as opposed to waiting until later stages. Our panelists discuss the results of this trial and its implications for patients.

Moderator: Ken Herrmann, MD (Universitätsmedizin Essen, Essen, Germany)

Panelists: Simron Singh, MD (Sunnybrook Research Institute, Toronto, Ontario, Canada), and Lisa Bodei, MD, PhD (Memorial Sloan Kettering Cancer Center, New York, New York, United States)

Thank you to SOFIE Biosciences for sponsoring this episode.

YouTube: Bringing PRRT to First Line: NETTER-2

Audio: Bringing PRRT to First Line: NETTER-2

Episode 5 – Healthcare Systems Readiness: What is Limiting the RLT Scale-up?
Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it.

Moderator: Ken Herrmann, MD (Universitätsmedizin Essen, Essen, Germany)

Panelist: Andrei Iagaru, MD (Stanford University Medical Center, Stanford, California), Leonhard Schaetz (Novartis, Basel, Switzerland), and Désirée Deandreis, MD (Gustave Roussy, Villejuif, France)

Thank you to SOFIE Biosciences for sponsoring this episode.

YouTube: Healthcare Systems Readiness: What is Limiting the RLT Scale-up?

Audio: Healthcare Systems Readiness: What is Limiting the RLT Scale-up?

Episode 4 – The Standard of Care for Metastatic Prostate Cancer
The VISION Trial is the first-in-its-field study to use radiopharmaceuticals that directly target prostate cancer tumors. Hear from one of the lead researchers on this ground-breaking study as he discusses how the trial has opened up a completely new field of study in prostate cancer research and shaped the future of nuclear medicine therapy in combatting the disease. Join us for Episode 4 of JNM Podcast from The Journal of Nuclear Medicine.

Moderators: Ken Herrmann, MD (Universitätsmedizin Essen, Essen, Germany) and Heiko Schoder, MD, MBA (Memorial Sloan Kettering Cancer Center)

Panelists: Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center)

Thank you to SOFIE Biosciences for sponsoring this episode.

YouTube: The Standard of Care for Metastatic Prostate Cancer

Audio: The Standard of Care for Metastatic Prostate Cancer

Episode 3 – Alpha is more than just ²²⁵Ac: ²¹²Pb
Recorded April 3, 2024
This episode of the JNM Podcast takes the discussion of Pb-212 worldwide! Researchers from the UK, Australia, and North America discuss the logistics of using lead-212 as a radionuclide imaging agent. From availability to production to transportation, Pb-212 presents both great opportunities and great challenges.

Moderator Ken Herrmann, MD, leads this intercontinental panel in a discussion about other radionuclides and their pros and cons. He's joined by David Bauer, PhD, from Memorial Sloan Kettering Cancer Center, Jane Sosabowski, BSc, MSc, PhD, from Queen Mary, University of London, and Nick Fletcher, PhD, from the University of Queensland, Australia.

YouTube: Alpha is More Than Just Ac-225: Pb-212

Audio: Alpha is More Than Just Ac-225: Pb-212

Episode 2 – Dementia Imaging
Recorded March 27, 2024
The Journal of Nuclear Medicine presents a new podcast on advances in dementia imaging. Panelists discuss the importance of amyloid and tau PET imaging in dementia diagnosis and treatment, highlighting their roles in clinical trials and future therapies. They emphasize the significance of early detection and the potential for personalized medicine approaches. Panel:

• Ken Herrmann, MD (Universitätsmedizin Essen, Essen, Germany)
• Henryk Barthel, MD, PhD (Leipzig University)
• Gil Rabinovici, MD (University of California - San Francisco)
• Victor Villemagne, MD (University of Pittsburgh)

YouTube: Advances in Dementia Imaging: Insights from Experts

Audio: Advances in Dementia Imaging: Insights from Experts

Episode 1 – The Future of FAPI Therapy
Released January 24, 2024
Explore FAPI-directed theranostics in cancer care with moderator Ken Herrmann and panelists delve into FAP history, challenges, and the road to clinical success.

YouTube: The Future of FAPI Therapy

Audio: The Future of FAPI Therapy